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In supplement 1 of volume 3 of Journal of Thoracic Oncology a late-breaking abstract did not appear. The abstract appears
below.
This error has been corrected in the online version of the supplement at www.jto.org.
LATE BREAKING ABSTRACT
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SORAFENIB PLUS CARBOPLATIN/PACLITAXEL IN
CHEMONAIVE PATIENTS WITH STAGE IIIB-IV NON–
SMALL CELL LUNG CANCER (NSCLC): INTERIM
ANALYSIS (IA)RESULTSFROMTHEPHASE III, RANDOM-
IZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,
ESCAPE (EVALUATION OF SORAFENIB, CARBOPLATIN,
AND PACLITAXEL EFFICACY IN NSCLC) TRIAL
G. Scagliotti1, J. von Pawel2, M. Reck3, L. Cupit4, F. Cihon4, S. DiMatteo4,
J. O’Leary4, N. Hanna5 1University of Turin, Turin/ITALY; 2Asklepios-Fach-
kliniken Munich-Gauting, Gauting/GERMANY; 3Hospital Grosshansdorf,
Grosshansdorf/GERMANY; 4Bayer Pharmaceuticals Corp, West Haven,
Connecticut/USA; 5Indiana University School of Medicine, Indianap-
olis, Minnesota/USA
Background: Sorafenib is an oral multikinase inhibitor with anti-angio-
genic and antiproliferative activity via inhibition of VEGFRs, PDGFRs,
c-Kit, Flt-3, RET, and Raf kinase, and single-agent activity in phase I–II
NSCLC trials.
Methods: Eligible pts had unresectable stage IIIB/IV NSCLC, no prior
systemic treatment, ECOG PS 0–1, and a life expectancy of_12 weeks.
Patients were randomized to receive carboplatin AUC 6 d1_paclitaxel 200
mg/m2 d1 combined with either sorafenib 400 mg (PCS) or placebo (PCP)
orally, bid d2–19, q3w. Daily sorafenib 400 mg bid or placebo was
continued as maintenance therapy following up to 6 cycles of chemother-
apy. Safety and efficacy was monitored by the DMC throughout the study.
The DMC recommended termination of the study for futility based on
findings from a formal planned IA of efficacy at 384 death events. Results:
926 patients were randomized to treatment with PCS (n_464) or PCP
(n_462). Overall demographics were balanced between arms and included:
63% male; 59% ECOG PS 1; 90% Stage IV disease; median age, 62 years
and 24% squamous cell (SC) histology (219 pts). Baseline demographics
were similar between SC and non-SC subsets. Preliminary efficacy results
revealed median overall survival (ITT analysis) 10.7 months in the PCS group
vs 10.6 months in the PCP group [HR (PCS/PCP), 95% CI_1.16, (0.95,1.43);
P_0.93, 1-sided]. From safety data currently available, the most common
causes of death in the ITT group were: PD, 292 (31.5%); other, 43 (4.6%);
unknown, 11 (1.2%); study treatment toxicity, 9 (1.0%); and pneumonia, 4
(0.4%). Greater mortality was observed in the subset of patient with SC
treated with PCS, compared with those treated with PCP. Cause of death in
SC subset was PD 63 (28.8%), other 11 (5.0%), unknown 5 (2.3%), study
treatment toxicity 4 (1.8%) and respiratory failure 2 (0.9%). Fatal pulmonary
hemorrhage was reported in 13 pts (1.4%) overall, with 9 events in the SCC
subset (5 in PCS group, 4 in PCP group). Conclusions: Based on this planned
interim analysis, there was no clinical benefit from the addition of sorafenib
to standard PC chemotherapy in NSCLC. PCS-treated patients with squa-
mous-cell NSCLC (n_107) had a greater mortality rate than those receiving
PCP (n_112). As the final, cleaned, database becomes available, additional
analyses will be performed to detect possible explanations for the efficacy and
safety outcomes of the trial.
Abstracts of the 1st European Lung Cancer Conference. J Thorac Oncol 2008;3(4 Suppl 1):S1–S106.
In the article “Induction Chemotherapy with Carboplatin, Irinotecan, and Paclitaxel Followed by High Dose Three-
Dimension Conformal Thoracic Radiotherapy (74 Gy) with Concurrent Carboplatin, Paclitaxel, and Gefitinib in Unresect-
able Stage IIIA and Stage IIIB, Non-small Cell Lung Cancer,” which appeared in volume 3 of the Journal of Thoracic
Oncology on pages 250–257, the rate of esophagitis reported in the abstract, text, and table should be 19%.
The journal regrets this error.
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